Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austco HealthcareASX:AHC -3.09%60 Return-on-Tangible-Equity is 35.11% as of Dec. 2025, which is 154% above its 10-year median of 13.81. GuruFocus rates ASX:AHC with a GF Score™ of 60/100 and a GF Value™ of A$0.33 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 760 Medical Devices & Instruments companies, Austco Healthcare ranks better than 88.42% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Austco Healthcare's annualized net income for the quarter that ended in Dec. 2025 was A$9.50 Mil. Austco Healthcare's average shareholder tangible equity for the quarter that ended in Dec. 2025 was A$27.05 Mil. Therefore, Austco Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 35.11%.
The historical rank and industry rank for Austco Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
ASX:AHC'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -87.4 Med: 13.81 Max: 32.78
Current: 28.35
During the past 13 years, Austco Healthcare's highest Return-on-Tangible-Equity was 32.78%. The lowest was -87.40%. And the median was 13.81%.
ASX:AHC's Return-on-Tangible-Equity is ranked better than 88.42% of 760
companies
in the Medical Devices & Instruments industry
Industry Median: 4.03
vs ASX:AHC: 28.35
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Austco Healthcare Return-on-Tangible-Equity Related Terms
Austco Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Austco Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AHC vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Austco Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austco Healthcare Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austco Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Austco Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 35.11% mean?
Austco Healthcare (ASX:AHC) has a Return-on-Tangible-Equity of 35.11% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Austco Healthcare and its competitors. This is 154% above median its historical median of 13.81. According to the industry distribution chart, Austco Healthcare ranks #88 out of 760 companies in the Medical Devices & Instruments industry, placing it in the top 11.6%.
Is Austco Healthcare's Return-on-Tangible-Equity too high?
Austco Healthcare's current Return-on-Tangible-Equity of 35.11% is 154% above median its 10-year median of 13.81. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.03. Austco Healthcare's value of 35.11% is 771.2% above this industry median. Based on the distribution chart, Austco Healthcare ranks #88 out of 760 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austco Healthcare has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Austco Healthcare's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Austco Healthcare ranks #88 out of 760 companies for Return-on-Tangible-Equity. This places Austco Healthcare in the top 12% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 4.03. Austco Healthcare's value of 35.11% is 771.2% above this benchmark. While the company's 10-year median is 13.81 vs. the industry median of 4.03, Austco Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.03, based on 760 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austco Healthcare's current Return-on-Tangible-Equity of 35.11% is 771.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Austco Healthcare and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austco Healthcare's current Return-on-Tangible-Equity is 35.11%, which is 154% above median its own 10-year median of 13.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austco Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Austco Healthcare (ASX:AHC) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.33, compared to a current price of A$0.24 — trading 28.8% below its estimated fair value. The current Return-on-Tangible-Equity is 35.11%, which is 154% above median its 10-year median of 13.81 and 771.2% above the Medical Devices & Instruments industry median of 4.03. Austco Healthcare's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Austco Healthcare (ASX:AHC), the current Return-on-Tangible-Equity is 35.11% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austco Healthcare (ASX:AHC) Overvalued in 2026?
Based on GuruFocus' analysis, Austco Healthcare stock appears to be undervalued.
The current stock price of A$0.24 is trading 28.8% below its estimated GF Value™ of A$0.33.
GuruFocus considers Austco Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:AHC:
Return-on-Tangible-Equity: 35.11% (154% above median its 10-year median of 13.81)
GF Value™: A$0.33 vs. price of A$0.24 (28.8% below fair value)
Industry Position: 771.2% above the Medical Devices & Instruments median (#88 of 760)
No single metric tells the full story. See the ASX:AHC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austco Healthcare Ltd engages in the development and provision of electronic communications and clinical management solutions. It offers Tacera, a nurse call, and healthcare communication system for healthcare professionals and patient. The group is segmented into four geographic regions consisting of Australia/New Zealand, Asia, Europe, and North America.
60GF Score
Get the complete analysis for ASX:AHC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AHC has been successfully added to your 
